LT2457920T - Oligosacharidai, apimantys aminooksigrupę, ir jų konjugatai - Google Patents

Oligosacharidai, apimantys aminooksigrupę, ir jų konjugatai

Info

Publication number: LT2457920T
Authority: LT; Lithuania
Prior art keywords: oligosaccharides; conjugates; aminooxy group; aminooxy; group
Prior art date: 2007-01-18

Application number

LTEP11188506.7T

Other languages

English (en)

Inventor

Yunxiang Zhu

Seng H. Cheng

Canwen Jiang

Luis Z. Avila

Original Assignee

Genzyme Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-18

Filing date

2008-01-18

Publication date

2018-02-12

2008-01-18 Application filed by Genzyme Corporation filed Critical Genzyme Corporation

2018-02-12 Publication of LT2457920T publication Critical patent/LT2457920T/lt

Links

125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 title 1
229920001542 oligosaccharide Polymers 0.000 title 1
150000002482 oligosaccharides Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/738—Cross-linked polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Crystallography & Structural Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Neurology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

LTEP11188506.7T 2007-01-18 2008-01-18 Oligosacharidai, apimantys aminooksigrupę, ir jų konjugatai LT2457920T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88547107P	2007-01-18	2007-01-18

Publications (1)

Publication Number	Publication Date
LT2457920T true LT2457920T (lt)	2018-02-12

Family

ID=39473250

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP11188504.2T LT2457919T (lt)	2007-01-18	2008-01-18	Oligosacharidai, apimantys aminooksi grupę, ir jų konjugatai
LTEP11188506.7T LT2457920T (lt)	2007-01-18	2008-01-18	Oligosacharidai, apimantys aminooksigrupę, ir jų konjugatai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP11188504.2T LT2457919T (lt)	2007-01-18	2008-01-18	Oligosacharidai, apimantys aminooksi grupę, ir jų konjugatai

Country Status (19)

Country	Link
US (5)	US8759501B2 (lt)
EP (5)	EP2457920B1 (lt)
JP (6)	JP5999867B2 (lt)
CN (2)	CN101631794B (lt)
CA (1)	CA2675968C (lt)
CY (2)	CY1119954T1 (lt)
DK (3)	DK2457920T3 (lt)
ES (3)	ES2656314T3 (lt)
FR (1)	FR22C1061I2 (lt)
HR (3)	HRP20130744T1 (lt)
HU (3)	HUE036140T2 (lt)
IL (3)	IL243117B2 (lt)
LT (2)	LT2457919T (lt)
NL (1)	NL301210I2 (lt)
NO (2)	NO2457920T3 (lt)
PL (3)	PL2457920T3 (lt)
PT (3)	PT2457919T (lt)
SI (2)	SI2457920T1 (lt)
WO (1)	WO2008089403A2 (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7723296B2 (en)	2001-01-18	2010-05-25	Genzyme Corporation	Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2008013735A2 (en) *	2006-07-21	2008-01-31	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
NO2457920T3 (lt) *	2007-01-18	2018-03-24
US8742079B2 (en)	2007-08-20	2014-06-03	Protalix Ltd.	Saccharide-containing protein conjugates and uses thereof
BRPI0923047B8 (pt)	2008-12-16	2021-05-25	Genzyme Corp	métodos para preparação de conjugados de proteínas- oligossacarídeos
US8962573B2 (en)	2009-07-03	2015-02-24	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Compounds targeting the cation-independent mannose 6-phosphate receptor
CA2769244A1 (en) *	2009-07-27	2011-02-03	Lipoxen Technologies Limited	Glycopolysialylation of non-blood coagulation proteins
NZ623810A (en) *	2009-07-27	2015-10-30	Lipoxen Technologies Ltd	Glycopolysialylation of non-blood coagulation proteins
US9194011B2 (en)	2009-11-17	2015-11-24	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
WO2011163572A2 (en)	2010-06-24	2011-12-29	University Of Kansas	Bifunctional conjugate compositions and associated methods
WO2012082635A1 (en) *	2010-12-13	2012-06-21	Ancora Pharmaceuticals, Inc.	Synthetic oligosaccharide group a streptococcus
WO2012098537A1 (en)	2011-01-20	2012-07-26	Protalix Ltd.	Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
CN105189542A (zh)	2013-02-20	2015-12-23	瓦莱里昂治疗有限责任公司	用于治疗庞贝氏症的方法和组合物
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
TWI821227B (zh)	2017-12-22	2023-11-11	美商健臻公司	胺甲喋呤誘發的免疫耐受性之生物標記
MX2021005245A (es) *	2018-11-08	2021-06-18	Kaleido Biosciences Inc	Composiciones de oligosacaridos y metodos de uso de las mismas.
US20230398224A1 (en)	2020-02-07	2023-12-14	Novartis Ag	Targeted plasma protein degradation
CN115715218A (zh)	2020-02-08	2023-02-24	建新公司	治疗庞贝病的组合物和方法
MX2022016019A (es)	2020-06-14	2023-04-10	Genzyme Corp	Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio.

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4701521A (en) *	1978-07-17	1987-10-20	The Trustees Of Boston University	Method of effecting cellular uptake of molecules
DE2940845B1 (de)	1979-10-09	1980-06-26	Ford Werke Ag	Kreiselpumpendichtung,insbesondere fuer Kuehlwasserpumpen in Kraftfahrzeugen
US4671958A (en) *	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
US5066789A (en) *	1988-09-30	1991-11-19	Neorx Corporation	Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
IL93432A (en)	1989-02-24	1994-02-27	Johnson Mathey Inc	Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) *	1989-02-24	1993-04-27	Johnson Matthey, Inc.	Certain pyridyl hydrazines and hydrazides useful for protein labeling
US5280113A (en) *	1989-08-16	1994-01-18	Monsanto Company	Method for producing synthetic N-linked glycoconjugates
US5212298A (en) *	1989-08-16	1993-05-18	Monsanto Company	Method for producing synthetic N-linked glycoconjugates
US5324663A (en) *	1990-02-14	1994-06-28	The Regents Of The University Of Michigan	Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5583042A (en) *	1990-04-16	1996-12-10	Neose Pharmaceuticals, Inc.	Apparatus for the synthesis of saccharide compositions
US5153312A (en) *	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
US5492821A (en) *	1990-11-14	1996-02-20	Cargill, Inc.	Stabilized polyacrylic saccharide protein conjugates
WO1992016212A1 (en) *	1991-03-13	1992-10-01	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
CA2101918A1 (en)	1991-03-18	1992-09-19	Samuel Zalipsky	Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
FR2721612B1 (fr) *	1994-06-23	1996-08-09	Idm	Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US6132764A (en) *	1994-08-05	2000-10-17	Targesome, Inc.	Targeted polymerized liposome diagnostic and treatment agents
US6071890A (en)	1994-12-09	2000-06-06	Genzyme Corporation	Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6118045A (en) *	1995-08-02	2000-09-12	Pharming B.V.	Lysosomal proteins produced in the milk of transgenic animals
AUPO190596A0 (en) *	1996-08-26	1996-09-19	Alchemia Pty Ltd	Oligosaccharide synthesis
JP4290766B2 (ja) *	1997-01-21	2009-07-08	サノフィ・パスツール	多糖―ペプチド複合体
US5952516A (en)	1997-05-08	1999-09-14	Genzyme Corporation	Cationic amphiphiles containing multiplesteroid lipophilic groups
EP1027069B1 (en)	1997-10-29	2006-07-26	Genzyme Corporation	Gene therapy for gaucher disease
US6287857B1 (en)	1998-02-09	2001-09-11	Genzyme Corporation	Nucleic acid delivery vehicles
US6538117B1 (en) *	1999-08-10	2003-03-25	The Scripps Research Institute	Programmable one-pot oligosaccharide synthesis
JP2004505885A (ja) *	1998-08-19	2004-02-26	ノース　アメリカン　ワクチン，　インコーポレイテッド	Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
US6399575B1 (en) *	1998-11-10	2002-06-04	Auburn University	Methods and compositions for targeting compounds to the central nervous system
EP1035137A1 (en)	1999-03-12	2000-09-13	Pasteur Merieux Serums Et Vaccins	Method for the reductive amination of polysaccharides
AU779887B2 (en) *	1999-06-08	2005-02-17	La Jolla Pharmaceutical Company	Valency platform molecules comprising aminooxy groups
US6770468B1 (en) *	1999-09-14	2004-08-03	Genzyme Glycobiology Research Institute, Inc.	Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6537785B1 (en) *	1999-09-14	2003-03-25	Genzyme Glycobiology Research Institute, Inc.	Methods of treating lysosomal storage diseases
WO2001060412A2 (en)	2000-02-15	2001-08-23	Genzyme Corporation	Modification of biopolymers for improved drug delivery
US6749865B2 (en) *	2000-02-15	2004-06-15	Genzyme Corporation	Modification of biopolymers for improved drug delivery
US20040067527A1 (en)	2000-07-26	2004-04-08	Sara Lavi	Intracellular delivery system for protein phosphatases and other polypeptides
JP2004507467A (ja) *	2000-08-18	2004-03-11	マサチューセッツ　インスティテュート　オブ　テクノロジー	オリゴ糖の自動化合成のための装置及び方法
US6676963B1 (en) *	2000-10-27	2004-01-13	Barnes-Jewish Hospital	Ligand-targeted emulsions carrying bioactive agents
US7001994B2 (en) *	2001-01-18	2006-02-21	Genzyme Corporation	Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en)	2001-01-18	2010-05-25	Genzyme Corporation	Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) *	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7629309B2 (en) *	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
DE60224816T2 (de) *	2001-04-30	2009-01-22	ZyStor Therapeutics, Inc., Milwaukee	Subzelluläres targeting von therapeutischen proteinen
WO2001090139A2 (en)	2001-05-07	2001-11-29	Supratek Pharma Inc.	A ligand for enhancing oral and cns delivery of biological agents
BR122015016313B8 (pt)	2001-07-16	2021-05-25	Genzyme Corp	composto semelhante à ceramida e método de preparar um composto
ES2561985T3 (es)	2001-10-10	2016-03-01	Ratiopharm Gmbh	Remodelación y glicoconjugación de anticuerpos
US7265084B2 (en) *	2001-10-10	2007-09-04	Neose Technologies, Inc.	Glycopegylation methods and proteins/peptides produced by the methods
AU2002348261A1 (en)	2001-11-26	2003-06-10	Genzyme Corporation	Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6905856B2 (en) *	2001-12-21	2005-06-14	Genzyme Glycobiology Research Institute, Inc.	Soluble GlcNAc phosphotransferase
US6800472B2 (en) *	2001-12-21	2004-10-05	Genzyme Glycobiology Research Institute, Inc.	Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
ES2496493T3 (es)	2002-01-11	2014-09-19	Bioasis Technologies Inc.	Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
TWI295483B (en)	2002-01-31	2008-04-01	Sumitomo Chemical Co	3-5 group compound semiconductor, process for producing the same, and compound semiconductor element using the same
EP1585817B1 (en) *	2002-02-20	2009-09-02	The General Hospital Corporation	Conjugates comprising a biodegradable polymer and uses therefor
US6916802B2 (en) *	2002-04-29	2005-07-12	Genzyme Corporation	Amino ceramide-like compounds and therapeutic methods of use
DE02020425T1 (de) *	2002-09-11	2004-07-15	Fresenius Kabi Deutschland Gmbh	Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
WO2004024776A1 (en)	2002-09-11	2004-03-25	Fresenius Kabi Deutschland Gmbh	Method of producing hydroxyalkyl starch derivatives
US20050026823A1 (en) *	2003-06-20	2005-02-03	Biomarin Pharmaceutical Inc.	Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en)	2003-06-20	2005-01-13	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
WO2005014035A2 (en)	2003-08-08	2005-02-17	Novo Nordisk Health Care Ag	Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
RU2327703C2 (ru)	2003-08-12	2008-06-27	Лайпоксен Текнолоджиз Лимитед	Производные полисиаловой кислоты
US7442372B2 (en) *	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
EP1525890A1 (en)	2003-10-02	2005-04-27	Complex Biosystems GmbH	Protein-Proteophore complexes
US7176185B2 (en) *	2003-11-25	2007-02-13	Tsrl, Inc.	Short peptide carrier system for cellular delivery of agent
CA2556169C (en) *	2004-01-29	2011-11-22	Andrew Lees	Use of amino-oxy functional groups in the preparation of vaccines
WO2005077093A2 (en)	2004-02-06	2005-08-25	Biomarin Pharmaceutical Inc.	Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
SI1740204T1 (en)	2004-04-01	2018-07-31	Chiesi Farmaceutici S.P.A.	MEDICAL APPLICATION OF ALFA-MANOSIDES
US8017151B2 (en) *	2004-09-07	2011-09-13	Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center	Amphiphilic polymer-protein conjugates and methods of use thereof
US7341720B2 (en)	2005-04-06	2008-03-11	Genzyme Corporation	Targeting of glycoprotein therapeutics
NO2457920T3 (lt)	2007-01-18	2018-03-24
WO2008089339A2 (en)	2007-01-18	2008-07-24	Genzyme Corporation	Oligosaccharide conjugates for cellular targeting
BRPI0923047B8 (pt) *	2008-12-16	2021-05-25	Genzyme Corp	métodos para preparação de conjugados de proteínas- oligossacarídeos

2008
- 2008-01-18 NO NO11188506A patent/NO2457920T3/no unknown
- 2008-01-18 EP EP11188506.7A patent/EP2457920B1/en active Active
- 2008-01-18 IL IL243117A patent/IL243117B2/en unknown
- 2008-01-18 ES ES11188506.7T patent/ES2656314T3/es active Active
- 2008-01-18 JP JP2009546533A patent/JP5999867B2/ja active Active
- 2008-01-18 LT LTEP11188504.2T patent/LT2457919T/lt unknown
- 2008-01-18 HU HUE11188506A patent/HUE036140T2/hu unknown
- 2008-01-18 DK DK11188506.7T patent/DK2457920T3/en active
- 2008-01-18 PL PL11188506T patent/PL2457920T3/pl unknown
- 2008-01-18 HU HUE11188504A patent/HUE045046T2/hu unknown
- 2008-01-18 CN CN2008800076802A patent/CN101631794B/zh active Active
- 2008-01-18 WO PCT/US2008/051429 patent/WO2008089403A2/en active Application Filing
- 2008-01-18 CA CA2675968A patent/CA2675968C/en not_active Expired - Fee Related
- 2008-01-18 SI SI200831908T patent/SI2457920T1/en unknown
- 2008-01-18 EP EP19177425.6A patent/EP3597655B1/en active Active
- 2008-01-18 SI SI200832088T patent/SI2457919T1/sl unknown
- 2008-01-18 DK DK11188504.2T patent/DK2457919T3/da active
- 2008-01-18 PL PL11188504T patent/PL2457919T3/pl unknown
- 2008-01-18 EP EP08727910.5A patent/EP2121713B1/en active Active
- 2008-01-18 PT PT11188504T patent/PT2457919T/pt unknown
- 2008-01-18 ES ES08727910T patent/ES2417146T3/es active Active
- 2008-01-18 CN CN201210469389.5A patent/CN102978185B/zh active Active
- 2008-01-18 PL PL08727910T patent/PL2121713T3/pl unknown
- 2008-01-18 DK DK08727910.5T patent/DK2121713T3/da active
- 2008-01-18 EP EP11188504.2A patent/EP2457919B1/en active Active
- 2008-01-18 EP EP23187944.6A patent/EP4293112A3/en active Pending
- 2008-01-18 PT PT87279105T patent/PT2121713E/pt unknown
- 2008-01-18 ES ES11188504T patent/ES2744574T3/es active Active
- 2008-01-18 LT LTEP11188506.7T patent/LT2457920T/lt unknown
- 2008-01-18 PT PT111885067T patent/PT2457920T/pt unknown
- 2008-01-18 US US12/523,631 patent/US8759501B2/en active Active
2009
- 2009-07-16 IL IL199925A patent/IL199925A/en active IP Right Grant
2012
- 2012-11-01 IL IL222792A patent/IL222792A0/en active IP Right Grant
2013
- 2013-08-06 HR HRP20130744AT patent/HRP20130744T1/hr unknown
2014
- 2014-05-08 US US14/272,960 patent/US9469850B2/en active Active
- 2014-10-03 JP JP2014204593A patent/JP6039625B2/ja active Active
2016
- 2016-09-29 US US15/280,864 patent/US20170014520A1/en not_active Abandoned
- 2016-11-02 JP JP2016214773A patent/JP6309592B2/ja active Active
2018
- 2018-01-16 HR HRP20180076TT patent/HRP20180076T1/hr unknown
- 2018-01-24 CY CY20181100094T patent/CY1119954T1/el unknown
- 2018-03-13 JP JP2018044959A patent/JP2018109194A/ja active Pending
2019
- 2019-02-06 US US16/268,989 patent/US10907142B2/en active Active
- 2019-08-30 HR HRP20191562 patent/HRP20191562T1/hr unknown
- 2019-09-04 CY CY20191100928T patent/CY1122452T1/el unknown
2020
- 2020-08-07 JP JP2020134331A patent/JP2020185011A/ja active Pending
2021
- 2021-09-10 US US17/472,367 patent/US20220204963A1/en not_active Abandoned
2022
- 2022-07-15 JP JP2022113593A patent/JP2022137232A/ja active Pending
- 2022-12-09 NO NO2022056C patent/NO2022056I1/no unknown
- 2022-12-15 FR FR22C1061C patent/FR22C1061I2/fr active Active
- 2022-12-16 NL NL301210C patent/NL301210I2/nl unknown
- 2022-12-19 HU HUS2200055C patent/HUS2200055I1/hu unknown

Also Published As

Publication number	Publication date
EP3597655B1 (en)	2023-08-02
IL199925A0 (en)	2010-04-15
CA2675968C (en)	2019-05-21
JP2020185011A (ja)	2020-11-19
DK2121713T3 (da)	2013-06-24
ES2656314T3 (es)	2018-02-26
CN102978185B (zh)	2015-02-11
US20170014520A1 (en)	2017-01-19
CN101631794B (zh)	2013-01-02
PL2121713T3 (pl)	2013-11-29
PL2457920T3 (pl)	2018-03-30
JP5999867B2 (ja)	2016-09-28
HRP20180076T1 (hr)	2018-02-23
US10907142B2 (en)	2021-02-02
CN101631794A (zh)	2010-01-20
ES2744574T3 (es)	2020-02-25
JP6039625B2 (ja)	2016-12-07
US20200010825A1 (en)	2020-01-09
HUE036140T2 (hu)	2018-06-28
EP2457920B1 (en)	2017-10-25
HRP20130744T1 (hr)	2013-10-11
PL2457919T3 (pl)	2019-12-31
CY1119954T1 (el)	2018-12-12
US8759501B2 (en)	2014-06-24
WO2008089403A3 (en)	2008-11-13
EP2121713A2 (en)	2009-11-25
EP4293112A3 (en)	2024-03-13
PT2457919T (pt)	2019-09-20
NL301210I2 (nl)	2023-02-02
JP2018109194A (ja)	2018-07-12
CA2675968A1 (en)	2008-07-24
CY1122452T1 (el)	2021-01-27
IL243117B (en)	2022-11-01
IL199925A (en)	2017-09-28
EP2457919A1 (en)	2012-05-30
NO2022056I1 (no)	2022-12-09
HUS2200055I1 (hu)	2023-01-28
PT2121713E (pt)	2013-06-25
WO2008089403A2 (en)	2008-07-24
EP2457919B1 (en)	2019-06-05
ES2417146T3 (es)	2013-08-06
FR22C1061I2 (fr)	2023-11-17
NO2457920T3 (lt)	2018-03-24
JP6309592B2 (ja)	2018-04-11
IL243117B2 (en)	2023-03-01
HRP20191562T1 (hr)	2019-11-29
EP3597655A1 (en)	2020-01-22
PT2457920T (pt)	2018-01-23
US9469850B2 (en)	2016-10-18
SI2457919T1 (sl)	2019-10-30
SI2457920T1 (en)	2018-02-28
EP4293112A2 (en)	2023-12-20
DK2457919T3 (da)	2019-09-16
JP2010516257A (ja)	2010-05-20
FR22C1061I1 (fr)	2023-02-03
US20150050262A1 (en)	2015-02-19
JP2015078360A (ja)	2015-04-23
LT2457919T (lt)	2019-09-25
EP2121713B1 (en)	2013-06-12
JP2017052962A (ja)	2017-03-16
US20220204963A1 (en)	2022-06-30
HUE045046T2 (hu)	2019-12-30
IL243117A (lt)	2016-01-31
EP2457920A1 (en)	2012-05-30
NL301210I1 (nl)	2022-12-21
CN102978185A (zh)	2013-03-20
JP2022137232A (ja)	2022-09-21
DK2457920T3 (en)	2018-01-22
US20100047225A1 (en)	2010-02-25
IL222792A0 (en)	2012-12-31

Publication	Publication Date	Title
HUS2200055I1 (hu)	2023-01-28	Aminooxi-csoportot tartalmazó oligoszacharidok és konjugátumaik
IL283205A (en)	2021-06-30	Attached medicinal substance that binds to cells, preparations containing them and their uses
HUS2100013I1 (hu)	2021-05-28	Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények
PT1988910T (pt)	2018-02-07	Acriloiloxietilfosforilcolina contendo conjugados de polímeros e sua preparação
ZA201001206B (en)	2010-12-29	Saccharide-containing protein conjugates and uses thereof
HK1149034A1 (en)	2011-09-23	Immunoconjugates targeting cd138 and uses thereof cd138
ZA201004609B (en)	2011-09-28	Polypeptide-nucleic acid conjugates and uses thereof
ZA201103043B (en)	2012-07-25	Etoposide and doxorubicin conjugates for drug delivery
ZA201006763B (en)	2012-03-28	Drug fusions and conjugates
ZA201201218B (en)	2012-11-28	3-polylysine conjugates and the use thereof
EP2370472A4 (en)	2013-04-24	LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
IL218869A (en)	2016-12-29	Oligomer-calcimimetic couplings and preparations containing them
SI2121713T1 (sl)	2013-08-30	Oligosaharidi, ki obsegajo aminooksi skupino, in njihovi konjugati
IL202849A0 (en)	2011-08-01	Targeting conjugates comprising active agent encapsulated in cyclodextrin-containing polymers